Elizabeth E Krans1,2, Susan L Zickmund3, Vinod K Rustgi4, Seo Young Park4, Shannon L Dunn2, Eleanor B Schwarz5. 1. a Department of Obstetrics , Gynecology and Reproductive Sciences , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA. 2. b Magee-Womens Research Institute , Pittsburgh , Pennsylvania , USA. 3. c Center for Health Equity Research and Promotion , Veteran's Administration (VA) Pittsburgh Healthcare System , Pittsburgh , Pennsylvania , USA. 4. d Department of Medicine , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA. 5. e Department of General Internal Medicine , University of Pittsburgh School of Medicine , Pittsburgh , Pennsylvania , USA.
Abstract
BACKGROUND: The purpose of this study was to describe the delivery of prenatal care services to women with opioid use disorder (OUD) on opioid maintenance therapy at high risk for hepatitis C virus (HCV) infection. METHODS: We conducted a retrospective cohort evaluation of 791 pregnant women with OUD from 2009 to 2012. HCV screening was defined as documentation of (a) an anti-HCV antibody test or (b) a provider discussion regarding a known HCV diagnosis during pregnancy. Multivariate logistic regression was used to identify predictors of HCV screening during pregnancy. RESULTS: Among 791 pregnant women with OUD, 611 (77.2%) were screened for HCV infection and 369/611 (60.4%) were HCV positive. In multivariable analysis, patients who were married (odds ratio [OR] = 0.52; 95% confidence interval [CI] = 0.29, 0.91), used buprenorphine (OR = 0.45; 95% CI = 0.28, 0.71), and were cared for by private practice providers (OR = 0.29; 95% CI = 0.19, 0.45) were significantly less likely to be screened. In contrast, patients who used benzodiazepines (OR = 1.72; 95% CI = 1.02, 2.92), intravenous (IV) opioids (OR = 6.15; 95% CI = 3.96, 9.56), had legal problems (OR = 2.23; 95% CI = 1.12, 4.45), had children not in their custody (OR = 1.81; 95% CI = 1.01, 3.24), and who had a partner with substance abuse history (OR = 2.38; 95% CI = 1.23, 4.59) were significantly more likely to be screened. Of 369 HCV-positive patients, a new diagnosis of HCV was made during pregnancy for 108 (29.3%) patients. Only 94 (25.5%) had HCV viral load testing, 61 (16.5%) had HCV genotype testing, and 38 (10.4%) received an immunization for hepatitis A. Although 285 (77.2%) patients were referred to hepatology, only 71 (24.9%) attended the consultation. Finally, only 6 (1.6%) patients received HCV treatment 1 year following delivery. CONCLUSIONS: Prenatal care approaches to HCV infection remain inconsistent, and the majority of patients diagnosed with HCV infection during pregnancy do not receive treatment after delivery.
BACKGROUND: The purpose of this study was to describe the delivery of prenatal care services to women with opioid use disorder (OUD) on opioid maintenance therapy at high risk for hepatitis C virus (HCV) infection. METHODS: We conducted a retrospective cohort evaluation of 791 pregnant women with OUD from 2009 to 2012. HCV screening was defined as documentation of (a) an anti-HCV antibody test or (b) a provider discussion regarding a known HCV diagnosis during pregnancy. Multivariate logistic regression was used to identify predictors of HCV screening during pregnancy. RESULTS: Among 791 pregnant women with OUD, 611 (77.2%) were screened for HCV infection and 369/611 (60.4%) were HCV positive. In multivariable analysis, patients who were married (odds ratio [OR] = 0.52; 95% confidence interval [CI] = 0.29, 0.91), used buprenorphine (OR = 0.45; 95% CI = 0.28, 0.71), and were cared for by private practice providers (OR = 0.29; 95% CI = 0.19, 0.45) were significantly less likely to be screened. In contrast, patients who used benzodiazepines (OR = 1.72; 95% CI = 1.02, 2.92), intravenous (IV) opioids (OR = 6.15; 95% CI = 3.96, 9.56), had legal problems (OR = 2.23; 95% CI = 1.12, 4.45), had children not in their custody (OR = 1.81; 95% CI = 1.01, 3.24), and who had a partner with substance abuse history (OR = 2.38; 95% CI = 1.23, 4.59) were significantly more likely to be screened. Of 369 HCV-positive patients, a new diagnosis of HCV was made during pregnancy for 108 (29.3%) patients. Only 94 (25.5%) had HCV viral load testing, 61 (16.5%) had HCV genotype testing, and 38 (10.4%) received an immunization for hepatitis A. Although 285 (77.2%) patients were referred to hepatology, only 71 (24.9%) attended the consultation. Finally, only 6 (1.6%) patients received HCV treatment 1 year following delivery. CONCLUSIONS: Prenatal care approaches to HCV infection remain inconsistent, and the majority of patients diagnosed with HCV infection during pregnancy do not receive treatment after delivery.
Entities:
Keywords:
Hepatitis C virus; opioid dependence; pregnancy; prenatal care screening
Authors: Hamisu M Salihu; Laura Connell; Jason L Salemi; Euna M August; Hanna E Weldeselasse; Amina P Alio Journal: J Womens Health (Larchmt) Date: 2011-10-19 Impact factor: 2.681
Authors: Laura F McNicholas; Amber M Holbrook; Kevin E O'Grady; Hendrée E Jones; Mara G Coyle; Peter R Martin; Sarah H Heil; Susan M Stine; Karol Kaltenbach Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Anthony J W Liu; Ethan I An; Henry G Murray; Emma Tetstall; Marcel J Leroi; Ralph K H Nanan Journal: Med J Aust Date: 2009-11-16 Impact factor: 7.738
Authors: Susan L Zickmund; Scott A Campbell; Carlos F Tirado; Carolyn L Zook; Robert M Weinrieb Journal: J Addict Med Date: 2012-09 Impact factor: 3.702
Authors: Elizabeth E Krans; Scott D Rothenberger; Penelope K Morrison; Seo Young Park; Leah C Klocke; Mary J Turocy; Susan Zickmund Journal: Matern Child Health J Date: 2018-08
Authors: Catherine A Chappell; Sharon L Hillier; David Crowe; Leslie A Meyn; Debra L Bogen; Elizabeth E Krans Journal: Pediatrics Date: 2018-05-02 Impact factor: 7.124
Authors: Susan M Lopata; Elizabeth McNeer; Judith A Dudley; Carolyn Wester; William O Cooper; James G Carlucci; Claudia M Espinosa; William Dupont; Stephen W Patrick Journal: Pediatrics Date: 2020-02-14 Impact factor: 7.124